Multi-center longitudinal quality assessment of MS-based proteomics in plasma and serum

Advancing MS-based proteomics towards clinical applications evolves around developing standardized start-to-finish and fit-for-purpose workflows for clinical specimens. Steps along the method design involve the determination and optimization of several bioanalytical parameters such as selectivity, sensitivity, accuracy, and precision. In a joint effort eight proteomics laboratories belonging to the MSCoreSys initiative including the CLINSPECT-M, MSTARS, DIASym, and SMART-CARE consortia performed a longitudinal round robin study to assess analysis performance of plasma and serum as clinically relevant samples. A variety of LC-MS/MS setups including mass spectrometer models from ThermoFisher and Bruker, as well as LC systems from ThermoFisher, Evosep, and Waters Corporation were used in this study. As key performance indicators sensitivity, precision and reproducibility were monitored over time. Protein identifications range between 300 to 400 IDs across different state-of-the-art MS instruments, with timsTOF Pro, Orbitrap Exploris 480 and Q Exactive HF-X being among the top performers. Overall, 71 proteins are reproducibly detectable in all setups in both serum and plasma samples and 22 of these proteins are FDA-approved biomarkers, which are reproducibly quantified (CV < 20% with label-free quantification). In total, the round robin study highlights a promising baseline for bringing MS-based measurements of serum and plasma samples closer to clinical utility.